Belimumab was recently shown to reduce disease activity in patients with systemic lupus erythematosus. This observation raises important questions about where belimumab might best fit into the ...

Panelists discuss the differences in efficacy and safety profiles between belimumab and voclosporin for lupus nephritis (LN) and how payers are evaluating their value, including considerations of cost ...

Kezar’s decision to terminate the PALIZADE IIb trial comes after it was placed on a clinical hold due to four patient deaths.

particularly glucocorticoids Using antimalarials and immunosuppressives both to control disease in the long term and avoid 'spare' glucocorticoids Belimumab Minor arthritis, mild pleurisy NSAIDs ...

Belimumab added to standard of care induction therapy improved control of disease activity and led to a reduction in glucocorticoid dosages in real-world patients with proliferative lupus nephritis.

Panelists discuss the differences in efficacy and safety profiles between belimumab and voclosporin for lupus nephritis (LN) and how payers are evaluating their value, including considerations of cost ...

Furie et al. now report favorable results for their phase I trial of belimumab—a fully human, neutralizing, monoclonal antibody against B-lymphocyte stimulator—which both stimulates ...

While GSK’s Benlysta (belimumab) and Aurinia’s Lupkynis (voclosporin) have been important advances in the treatment arsenal for lupus nephritis (LN), a serious complication of systemic lupus ...

Benlysta is a different type of medicine called a biologic. Belimumab, the active ingredient in Benlysta, targets a specific type of cell in the immune system that plays a major role in lupus ...

Benlysta (belimumab) is a prescription drug that’s used to treat lupus and a complication of lupus. Benlysta’s cost may depend on factors such as your dosage, whether you have health insurance ...

with newer medicines like GSK's Benlysta (belimumab), AstraZeneca's Saphnelo (anifrolumab), and Otsuka's Lupkynis (voclosporin). For Biogen, dapirolizumab pegol is part of a push into the ...